2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Checkpoint Inhibitor, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

1933 Epcoritamab plus gemcitabine, dexamethasone, and cisplatin (Epco-GDP) demonstrates high complete response rates in relapsed/refractory large B-cell lymphoma eligible for autologous stem cell transplantation or CAR T-cell therapy: Results from a multicenter phase II investigator-initiated trial

Dipenkumar Modi, MD, Abhinav Deol, MD2, Jay Yang, MD3, Farrukh T Awan, M.D.M.S.,M.B.A.4, Elif Yilmaz, MD5, Vy Ong6, Seongho Kim, PhD7, Mary Domagalski, BS8, Emily Ayers, MD9, Rita Assi, MD10, Varun Mittal, MD11
1 Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States
2 Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States
3 Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States
4 UT Southwestern Medical Center, Dallas, United States
5 UT Southwestern Medical Center, Dallas, United States
6 Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States
7 Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States
8 Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States
9 University of Virginia, Charlottesville, United States
10 Indiana University, Indianapolis, United States
11 Indiana University, Indianapolis, United States

Background: Epcoritamab (Epco), a CD3×CD20 bispecific antibody, is approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after ≥2 prior lines of systemic therapy. Patients with R/R LBCL eligible for autologous stem cell transplantation (ASCT) or chimeric antigen receptor (CAR) T-cell therapy often require effective salvage or bridging therapy to achieve disease control before definitive treatment. Response to salvage or bridging chemotherapy is not satisfactory in primary refractory disease or those with prior rituximab exposure. We evaluated the safety and efficacy of Epco-GDP (Gemcitabine, Dexamethasone, Cisplatin) in patients with R/R LBCL eligible for ASCT or CAR T-cell therapy (ClinicalTrials.gov Identifier: NCT05852717).

Methods: This multicenter, investigator-initiated, phase II study enrolled patients with CD20-positive R/R LBCL who had received ≥1 prior line of therapy, including an anti-CD20 antibody, and were eligible for ASCT or CAR T-cell therapy. Patients received three 21-day cycles of outpatient Epco-GDP. Epcoritamab was administered subcutaneously using step-up dosing during cycle 1 (0.16/0.8/48 mg) followed by weekly 48-mg dosing. GDP consisted of gemcitabine 1000 mg/m² on days 1 and 8, cisplatin 75 mg/m² on day 1, and dexamethasone 40 mg orally on days 1–4. Patients could proceed to ASCT or CAR T-cell therapy after cycle 3 at investigator discretion. Patients not undergoing ASCT or CAR T-cell therapy could receive epcoritamab monotherapy at every 2 weeks for up to six additional 28-day cycles. The primary endpoint was complete response (CR) rate after three cycles according to Lugano criteria.

Results: As of April 24, 2026, 28 patients were enrolled. Median age was 62 years (range, 40–72); 89% had stage III/IV disease, 93% had diffuse large B-cell lymphoma, not otherwise specified, 25% had double-expressor lymphoma, and 3.6% had double-hit lymphoma. Forty percent had primary refractory disease, and the median number of prior therapies was two (range, 1–4). Eighty-six percent of patients received protocol defined three cycles of Epco-GDP.

Among 28 patients, the overall response rate was 82.1%, including a CR rate of 75%, meeting the primary endpoint. CR rate was 63.6% and 82.3% for primary refractory and relapsed disease, respectively. Of 28 patients, 11 received CAR T-cell therapy and 10 underwent ASCT. After a median follow-up of 14.8 months, estimated 18-month duration of response (DOR), progression-free survival (PFS), and overall survival (OS) were 57.9%, 58.5%, and 75.3%, respectively. Median DOR, PFS, and OS have not been reached. Cytokine release syndrome occurred in 14 patients (50%). Among the 13 patients with documented CRS grade, all events were grade 1–2. One patient had an unknown CRS grade. No immune effector cell-associated neurotoxicity syndrome was observed. Four patients (14.3%) required CRS-related hospitalization, and 4 (14.3%) received tocilizumab. Grade 3–4 treatment-related adverse events occurring in ≥20% of patients included thrombocytopenia (75%), anemia (42.86%), lymphocytopenia (32.14%), and neutropenia (25%).

Conclusions: Epco-GDP demonstrated high antitumor activity, with a 75% CR rate among treated patients with high-risk R/R LBCL eligible for ASCT or CAR T-cell therapy. The regimen was feasible in the outpatient setting and showed a manageable safety profile with predominantly low-grade CRS and no ICANS. Enrollment is ongoing toward the planned sample size of 32 efficacy-evaluable patients.

Dipenkumar Modi, MD: Regeneron - Honoraria; Dava Oncology - Honoraria; Genentech - Research Funding; Genmab - Research Funding; AstraZeneca - Research Funding; Karyopharm Therapeutics - Research Funding; AstraZeneca - Consultancy (Includes expert testimony); Bristol Meyers Squibb - Consultancy (Includes expert testimony); Scitech Development Inc - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Daiichi Sankyo - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Bristol-Meyers Squibb - Consultancy (Includes expert testimony)